Paratek Pharmaceuticals
Boston
About Paratek Pharmaceuticals
Paratek Pharmaceuticals is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed in both oral tablet and intravenous formulations for use as a first-line monotherapy antibiotic for ABSSSI, CABP, urinary tract infections (UTI), and other serious community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Omadacycline has received the Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for both the oral and intravenous formulations in all three of these infectious disease categories. Paratek has Special Protocol Assessment agreements with the FDA for the phase 3 trials planned in ABSSSI and CABP.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Total funding: $264.1M
- Funding stage: M&A
- Last round: Post-IPO Debt (Jan 2021)
- Ticker: nasdaq:PRTK
- Website: paratekpharma.com
- Phone: 1 (617)807-6600
Industries & Categories
Biopharma, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/paratek-pharmaceuticals-73550 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.